Biogen Idec's EMPOWER study fails to demonstrate efficacy

01/02/2013

Biogen Idec announced today that the results of their randomized, double-blind, placebo-controlled Phase 3 trial of dexpramipexol in people living with ALS, known as the EMPOWER study, failed to demonstrate efficacy in its primary or key secondary endpoints.

Although Biogen Idec will be discontinuing development of dexpramipexole in ALS at this time, the company has indicated that it remains steadfast in its commitment to find a potential new treatment for ALS.

Click to read a press release and a Q & A, prepared by Biogen Idec.  As more information becomes available we will pass it along to you as well as contact information at Biogen Idec for any further questions you may have.

In the face of this very disappointing news, we will continue, as we always have, to work our hardest to create a future rid of ALS.